Veloxis Pharmaceuticals Presents LCP-Tacro(TM) Phase 3 Data at the American ... MarketWatch (press release) The results presented today show that LCP-Tacro(TM) once-daily was associated with a trend towards reduction in the incidence of Biopsy Proven Acute Rejection (BPAR) and a tendency for less severe histological changes compared to Prograf® twice-daily. ... |
